Literature DB >> 22236025

Cardiac effects of HDL and its components on diabetic cardiomyopathy.

Frank Spillmann1, Sophie Van Linthout, Carsten Tschöpe.   

Abstract

Diabetic cardiopathy includes a specific cardiomyopathy, which occurs in the absence of coronary heart disease and hypertension under diabetes mellitus. Hyperglycemia, hyperinsulinemia, and hyperlipidemia, characteristic metabolic disturbances evident in diabetes mellitus, all three lead to a specific altered cardiac structure and function. Recently, it has been demonstrated that altered HDL, be it low HDL or dysfunctional HDL is not only a consequence of diabetes mellitus, but can also contribute to the development of diabetes mellitus, and therefore also of diabetic cardiomyopathy. This review summarizes how HDL can indirectly affect diabetic cardiomyopathy via their influence on the metabolic triggers hyperglycemia, hyperinsulinemia, and hyperlipidemia, and how they can directly influence the cardiac cellular consequences, typical for diabetic cardiomyopathy, including inflammation, oxidative stress, apoptosis, fibrosis, Ca2+ handling, glucose homeostasis, and endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236025     DOI: 10.2174/187153012800493521

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  7 in total

1.  αB-crystallin regulates oxidative stress-induced apoptosis in cardiac H9c2 cells via the PI3K/AKT pathway.

Authors:  Feng Xu; Haixia Yu; Jinyao Liu; Lu Cheng
Journal:  Mol Biol Rep       Date:  2012-12-01       Impact factor: 2.316

2.  Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways.

Authors:  Bin-Cheng Ren; Yu-Fei Zhang; Shan-Shan Liu; Xiao-Jing Cheng; Xin Yang; Xiao-Guang Cui; Xin-Rui Zhao; Hui Zhao; Min-Feng Hao; Meng-Dan Li; Yuan-Yuan Tie; Li Qu; Xue-Yi Li
Journal:  J Cell Mol Med       Date:  2020-09-22       Impact factor: 5.310

3.  Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy.

Authors:  QingQing Wang; Lili Guo; Cassandra J Strawser; Lauren A Hauser; Wei-Ting Hwang; Nathaniel W Snyder; David R Lynch; Clementina Mesaros; Ian A Blair
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

4.  Administration of apo A-I (Milano) nanoparticles reverses pathological remodelling, cardiac dysfunction, and heart failure in a murine model of HFpEF associated with hypertension.

Authors:  Mudit Mishra; Ilayaraja Muthuramu; Herman Kempen; Bart De Geest
Journal:  Sci Rep       Date:  2020-05-20       Impact factor: 4.379

Review 5.  Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases.

Authors:  Elena M G Diarte-Añazco; Karen Alejandra Méndez-Lara; Antonio Pérez; Núria Alonso; Francisco Blanco-Vaca; Josep Julve
Journal:  Int J Mol Sci       Date:  2019-12-12       Impact factor: 5.923

6.  Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout mice via endothelial-mesenchymal transition.

Authors:  Kun Ling Ma; Jing Liu; Jie Ni; Yang Zhang; Lin Li Lv; Ri Ning Tang; Hai Feng Ni; Xiong Zhong Ruan; Bi Cheng Liu
Journal:  Int J Med Sci       Date:  2013-02-28       Impact factor: 3.738

Review 7.  Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives.

Authors:  Luis E León; Sweta Rani; Mauricio Fernandez; Martín Larico; Sebastián D Calligaris
Journal:  J Diabetes Res       Date:  2015-12-06       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.